Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Bence Jones Protein

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    16 result(s) found for: Bence Jones Protein. Displaying page 1 of 1.
    EudraCT Number: 2005-000395-41 Sponsor Protocol Number: ICORG 05-01 Start Date*: 2005-05-27
    Sponsor Name:All Ireland co-operative Oncology Research Group
    Full Title: Phase II Study to Assess the Safety, Efficacy, and Tolerability of Combination Therapy with Velcade (Bortezomib), Adriamycin, and Dexamethasone (PAD) as Therapy for Patients with relapsed or refra...
    Medical condition: Relapsed or refractory Multiple Myeloma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-000026-31 Sponsor Protocol Number: ML18704 Start Date*: 2006-06-20
    Sponsor Name:Roche Austria GmbH
    Full Title: Bevacizumab as treatment for patients with relapsed/refractory multiple myeloma
    Medical condition: Multiple myeloma, relapsed/refractory after at least 2 lines of prior therapy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-000130-37 Sponsor Protocol Number: MM-SDX-105-01 Start Date*: 2014-09-12
    Sponsor Name:FONDAZIONE NEOPLASIE SANGUE ONLUS (FO.NE.SA. Onlus)
    Full Title: Prospective, phase II study to evaluate the efficacy and the safety of a combination of bendamustine-melphalan as preparative regimen to autologous transplantation of hematopoietic cells for multi...
    Medical condition: Multiple myeloma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-016839-35 Sponsor Protocol Number: PX-171-009 Start Date*: 2010-09-07
    Sponsor Name:Onyx Therapeutics, Inc.
    Full Title: Estudio en fase 3 multicéntrico y aleatorizado de comparación de carfilzomib, lenalidomida y dexametasona (CRd) con lenalidomida y dexametasona (Rd) en pacientes con mieloma múltiple recidivado. A...
    Medical condition: Mieloma múltiple. Multiple myeloma.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GB (Completed) BE (Completed) NL (Completed) CZ (Completed) DE (Completed) AT (Completed) BG (Completed) FR (Completed) HU (Completed) SE (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-016840-38 Sponsor Protocol Number: PX-171-011 Start Date*: 2010-04-22
    Sponsor Name:Onyx Therapeutics, Inc.
    Full Title: A Randomized, Open-label, Phase 3 Study of Carfilzomib vs Best Supportive Care in Subjects with Relapsed and Refractory Multiple Myeloma
    Medical condition: Multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    12.1 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) HU (Completed) CZ (Completed) ES (Completed) IT (Completed) GB (Completed) SE (Completed) SK (Completed) GR (Completed) DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2019-001027-12 Sponsor Protocol Number: IsKPd-IFM2018-03 Start Date*: 2019-10-07
    Sponsor Name:CHU de Poitiers
    Full Title: Multicenter Open label Phase 2 study of Isatuximab plus Pomalidomide and Dexamethasone with Carfilzomib in Relapsed or Refractory Multiple Myeloma
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-001416-20 Sponsor Protocol Number: DSC/07/2357/29 Start Date*: 2009-05-19
    Sponsor Name:ITALFARMACO
    Full Title: Phase II High Pulse Dose Clinical Trial of Orally Administered ITF 2357 In Patients with Relapsed/Refractory Multiple Myeloma
    Medical condition: Patients with Relapsed/Refractory Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028229 Multiple myelomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-001914-33 Sponsor Protocol Number: HM11/9825 Start Date*: 2011-10-20
    Sponsor Name:University of Leeds
    Full Title: A phase 1/2a, dose escalation study of CHR-3996 in combination with tosedostat in subjects with relapsed, refractory multiple myeloma
    Medical condition: Relpsed or refractory multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-004333-33 Sponsor Protocol Number: EMN22/54767414AMY2005 Start Date*: 2019-07-08
    Sponsor Name:European Myeloma Network
    Full Title: Phase 2 study of daratumumab monotherapy in previously untreated patients with stage 3B light chain (AL) amyloidosis
    Medical condition: Patients with newly diagnosed stage 3B AL amyloidosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10002022 Amyloidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Ongoing) NL (Ongoing) FR (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-021598-35 Sponsor Protocol Number: UCL/08/0255 Start Date*: 2010-08-26
    Sponsor Name:University College London
    Full Title: Phase II study of Bortezomib, Adriamycin and Dexamethasone (PAD) therapy for previously untreated patients with multiple myeloma: Impact of minimal residual disease (MRD) in patients with deferred ...
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-004490-10 Sponsor Protocol Number: 2012_32 Start Date*: 2013-09-18
    Sponsor Name:Ghent University Hospital
    Full Title: A Multicenter Open label Phase 2 study of Carfilzomib Weekly plus Melphalan and Prednisone in Untreated Symptomatic Elderly Multiple Myeloma.
    Medical condition: A Multicenter Open label Phase 2 study of Carfilzomib Weekly plus Melphalan and Prednisone in Untreated Symptomatic Elderly Multiple Myeloma.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-002670-12 Sponsor Protocol Number: HM16/235 Start Date*: 2017-03-21
    Sponsor Name:Univeristy of Leeds
    Full Title: MUK nine b: OPTIMUM. A phase II study evaluating multiple novel agentsoptimised combination of biological therapy in newly diagnosed high risk multiple myeloma and plasma cell leukaemia.
    Medical condition: Newly diagnosed high risk multiple myeloma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2017-001736-19 Sponsor Protocol Number: HM17/95228 Start Date*: 2017-12-20
    Sponsor Name:University of Leeds
    Full Title: A randomised phase II trial of Selinexor, cyclophosphamide and prednisolone vs cyclophosphamide and prednisolone in relapsed or refractory multiple myeloma (RRMM) patients
    Medical condition: Multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2018-001646-34 Sponsor Protocol Number: 18-070 Start Date*: 2019-01-11
    Sponsor Name:CHU CAEN
    Full Title: A MULTICENTRE OPEN-LABEL PHASE II STUDY OF IXAZOMIB -DARATUMUMAB WITHOUT DEXAMETHASONE (IDARA) IN ELDERLY RELAPSE REFRACTORY MULTIPLE MYELOMA.
    Medical condition: Elderly Relapse Refractory Multiple Myeloma Patients
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-002221-19 Sponsor Protocol Number: 2015_29 Start Date*: 2015-10-20
    Sponsor Name:CHRU of Lille
    Full Title: A Multicenter Open label Phase II study of Daratumumab in combination with dexamethasone in Multiple Myeloma resistant or refractory to Bortezomib and Lenalidomide and Pomalidomide – an IFM 2014-04...
    Medical condition: Multiple Myeloma resistant or refractory to Bortezomib and Lenalidomide and Pomalidomide
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-000506-35 Sponsor Protocol Number: UCL/12/0500 Start Date*: 2015-02-23
    Sponsor Name:University College London
    Full Title: Carfilzomib/Cyclophosphamide/Dexamethasone with maintenance carfilzomib in untreated transplant-eligible patients with symptomatic MM to evaluate the benefit of upfront ASCT
    Medical condition: Multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 20:57:06 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA